Halston Media publisher Brett Freeman argues in a Thanksgiving column that daily oral semaglutide helped him lose nearly 14 pounds and manage prediabetes after years of failed lifestyle changes.
Writing for Halston Media News, Freeman describes a family history of premature heart disease — his grandfather died at 55 and his father survived a heart attack at 56 — that motivated his mother and wife to press him toward medical treatment. He began taking the Wegovy pill in early June, choosing the oral formulation over weekly injections to fit his routine.
“I get full. Quickly,” Freeman writes of the drug’s effect on satiety. “The hunger feels more manageable, and a much smaller amount of food satisfies me.” He reports missing only one dose while on vacation and tolerating early nausea. His goal is to lose an additional 15 to 20 pounds.
Freeman frames the medication as a tool that compensates for a biology he could not control through willpower alone. “You can be extraordinarily disciplined in one part of your life and struggle in another,” he writes, comparing his entrepreneurial focus to Meta CEO Mark Zuckerberg’s simplified wardrobe. “If someone considers the medication an unfair assist, I can live with that.”
How Oral Semaglutide Alters Appetite Signaling
The active ingredient, semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics an incretin hormone released by the gut after eating, binding to receptors in the hypothalamus to reduce appetite and slow gastric emptying. The oral version uses a sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) carrier to protect the peptide from stomach acid and enhance absorption across the gastric mucosa.
Clinical trials for oral semaglutide, including the PIONEER program, demonstrated HbA1c reductions of 1.0 to 1.4 percentage points in type 2 diabetes and weight losses averaging 4.4 to 6.9 kilograms at 52 weeks depending on dose. The OASIS 1 trial, which evaluated 50 mg daily for obesity, showed a mean weight reduction of 15.1 percent versus 2.4 percent for placebo at 68 weeks.
Nausea Subsides During Dose Escalation
- Nausea is the most common side effect during dose escalation but often subsides within weeks.
- The pill must be taken on an empty stomach with a small sip of water, followed by a 30-minute wait before food or coffee.
Regulatory Status and Access Across Health Systems
The U.S. Food and Drug Administration approved oral semaglutide (Rybelsus) for type 2 diabetes in 2019. In 2023, the agency approved a higher-dose formulation (Wegovy) for chronic weight management, though the oral obesity indication remains under review. The European Medicines Agency and the UK Medicines and Healthcare products Regulatory Agency have authorized the diabetic formulation; the weight-loss indication varies by national reimbursement policy.
Funding and Evidence Base
Novo Nordisk, the drug’s manufacturer, funded the oral semaglutide trials. The OASIS 1 study was published in The Lancet in 2023. The STEP 1 trial for the injectable formulation appeared in The New England Journal of Medicine in 2021.
Contraindications and Medical Warnings Listed
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should not be used during pregnancy. Patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy complications require careful evaluation. Persistent severe abdominal pain, vomiting, or signs of allergic reaction warrant immediate medical attention.
Freeman founded Halston Media in 2010 and serves as its CEO and publisher. In 2019, the Somers Chamber of Commerce named him Businessperson of the Year, and he has also been recognized for leadership by the Somers Town Board and the Westchester County Board of Legislators. He previously received the Putnam Community Service Network’s Award for Excellence in Communications and the Somers Lions Club’s Robert J. Award for community service.
Freeman closes his column by linking his treatment decision to family longevity. “I want to see what my children do with their lives,” he writes. “Someday, I hope to have a close relationship with my grandchildren, as my parents do with my kids.”
References
- Davies MJ, et al. Oral semaglutide for weight loss in people with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. 2023.
- Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6). 2019.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). 2021.
- U.S. Food and Drug Administration. FDA approves Rybelsus (semaglutide) tablets for type 2 diabetes. 2019.
- European Medicines Agency. Rybelsus (semaglutide) summary of product characteristics. 2020.